Dexcom Inc DXCM

$81.39 +1.04 (1.30%)

Valuation

Market cap
29,964,748,000
Revenue TTM
$4,662,000,000
Net income TTM
$836,300,000
P/E (trailing)
29.93
P/E (forward)
29.86
Profit margin
17.94%
Debt to equity
0.49

Trading

Volume
4,087,100
Avg volume
4,357,920
Day's range
$79.38 – $82.51
Shares out
372,951,000
Stochastic %K
22%
Beta
1.45
Analysts
Strong Buy
Price target
$97.44

Price

Company profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for...

Show more

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Industry
Medical Devices
Sector
Healthcare
Phone
858 200 0200
Website
https://www.dexcom.com
Address
6340 Sequence Drive, San Diego, United States

Latest news

Stocktwits

openclassaction2 Nov 13, 4:19 AM
$DXCM three proposed suits allege dexcom failed to protect users personal and health info, breach unconfirmed, per open class actions. lawsuit stage, nothing to claim. seems like health data risk trades too
0 replies
darkpoolangel Nov 10, 3:09 PM
$SENS will take over $DXCM to be the king of CGM once Freedom and Gemini are released.
0 replies
Dr_Stoxx Nov 10, 2:10 PM
$DXCM weekly
0 replies
clan2pointOh Nov 10, 10:07 AM
$MNKD $DXCM Afrezza + G7 = Best TIR For the good of all {diabetic} Mannkind! 😲 $SPY 👀 #inhalemyinsulin #afrezza #fastinfastout
1 replies
HaliburtonResearch Nov 9, 10:37 PM
$DXCM might be a very good short-term play as customers max out their benefits before January 1st. Per Dexcom: "Dexcom is losing coverage under certain U.S. CVS Caremark and Aetna commercial pharmacy-benefit plans starting January 1, 2027. This is a specific insurer/formulary change, not a blanket loss of insurance coverage for Dexcom."
0 replies
doctortoboggan Nov 9, 2:21 PM
$DXCM CFO Jereme Sylvain confirmed that the specific CVS Caremark accounts moving to Abbott's FreeStyle Libre represent less than 4% of Dexcom's total annual revenue
1 replies
GTA_Terminal Nov 9, 2:00 PM
Dark pool check on $DXCM: what traded off the exchanges in the latest session. That came on a day the stock dropped hard, so the question is whether big holders were buying the dip or heading for the exit. Read the full article for the full details: https://globaltradersacademy.com/articles/dxcm-technical-levels-chart-options-flow-and-dark-pools-diverge-at-79-41?utm_source=stocktwits&utm_medium=social
0 replies
Etty Nov 8, 2:16 PM
$DXCM I recommend that stockholders check any of the type one diabetes groups on Facebook. Across the board, users are getting letters from pharmacies including CVS saying after the new year they will no longer cover Dexcom and will only provide libre. This is leaving many users whose pumps work with Dexcom in an awful spot and will greatly reduce sales. Could be because of the deaths and poor reliability of the 7. Not sure yet if the requested medical necessity exception for my child will be covered
0 replies